Table 2

CCND1 and EMS1 amplification by clinicopathological findings, site and relapse

Total casesCCND1-amplified cases (%)PaEMS1-amplified cases (%)Pa
Mean age (yr)58.757.40.38b58.80.98b
pT stage
T1–T2286 (21)0.121 (3.5)0.001
T3338 (24)4 (12)
T44318 (42)16 (37)
pN stage
N0355 (14)0.00545 (14)0.02
N1218 (38)1 (5)
N2329 (28)8 (25)
N31610 (62)7 (43)
Pathologic grade
Well-differentiated5115 (29)0.946 (12)0.018
Moderately differentiated4314 (32)10 (23)
Poorly differentiated103 (30)5 (50)
Disease stage
I–II1300.03600.041
III3011 (37)4 (13)
IV6121 (34)17 (28)
Site
Oral cavity51 (20)0.0871 (20)0.62
Oropharynx244 (17)6 (25)
Supraglottic larynx239 (39)2 (9)
Glottic larynx152 (13)3 (20)
Hypopharynx3716 (43)9 (24)
Recurrencec
No recurrence327 (22)0.1600.0004
Loco-regional recurrence4318 (42)16 (37)
Distant metastases123 (25)2 (17)
Disease status
Alive without disease358 (23)0.191 (3)0.0019
Dead of index cancer5220 (38)17 (33)
Died of other causes174 (24)3 (18)
  • a χ2 test.

  • b t test.

  • c Seventeen patients who died from causes not related to the index tumor were excluded from the recurrence analysis.